Africa Union, Johnson & Johnson agree on 400 Million Doses of COVID-19 Vaccines

The African union has successfully signed historic COVID-19 vaccine procurement Agreement with Johnson & Johnson for 400 Million Doses of COVID-19 Vaccines, according to AU chairman, President Cyril Ramaphosa.

Africa will have access to 220 million doses of the Johnson & Johnson single-shot COVID-19 vaccine, with the potential to order an additional 180 million doses.

Most of the supplies will be produced at the giant pharmaceutical manufacturing plant in South Africa operated by Aspen Pharma. The vaccines will be made available to African countries through the African Medical Supplies Platform (AMSP), over a period of 18 months.

The transaction was made possible through the US$2 billion facility approved by the African Export-Import Bank (Afreximbank), who also acted as Financial and Transaction Advisers, Guarantors, Installment Payment Advisers  and Payment Agents.

The successful conclusion of the Agreement was made possible by the support of the United Nations Economic Commission for Africa (ECA) and the United Nations International Children’s Emergency Fund (UNICEF), who supported the negotiation process with Johnson & Johnson.

UNICEF is also acting as procurement and logistics agent. The African Vaccine Acquisition Task Team (AVATT) was supported in terms of advice on various aspects by the World Health Organization (WHO).

Prior to the conclusion of the Agreement with Johnson & Johnson, African Member States were asked to make pre-orders for the vaccines and many countries showed strong preference for this particular vaccine.

The countries will be able to purchase the vaccines either using cash, or a facility from Afreximbank. Most countries have already completed their pre-orders.

The direct acquisition of vaccines by the African countries through the AVATT initiative is part of the continental objective to achieve a minimum of 60 percent immunization of the African population, in order to eliminate COVID-19.

“This Agreement is a significant milestone in protecting the health of all Africans. It is also a powerful demonstration of African unity and of what we can achieve through partnership between the state sector, the private sector and international institutions that puts people first,” said President Ramaphosa.

Benedict Oramah, President of Afreximbank, said: “Afreximbank is proud to be associated with this historic and collective effort. In the midst of a very tight COVID-19 vaccine market, we are highly honoured to have been given the opportunity by the African Union to facilitate this impactful transaction under the auspices of the Africa Vaccine Acquisition Task Team (AVATT).’’

Acting as Financial and Transaction Advisors, Guarantors, Installment Payment Facility Arrangers and Payment Agents, we look forward to beginning the deployment of the US$2 billion Vaccine Procurement facility approved by the Bank’s Board of Directors towards assisting the continent to begin to rid itself of the pandemic and rebuild its economy, he added.

John Nkengasong, Director of the Africa Centres for Disease Control and Prevention (Africa CDC), said: “The Africa CDC recommended to the African Union that a minimum of 750 million Africans (60%) must be immunized if we are to contain the spread of COVID-19. This transaction enables Africa to meet almost 50% of that target. The key to this particular vaccine is that it is a single-shot vaccine which makes it easier to roll out quickly and effectively, thus saving lives.